In people with type 2 diabetes who also use insulin or insulin-stimulating drugs, such as sulfonylureas, the risk of low blood sugar, also called hypoglycemia, may be increased, so the doses of those medicines may need to be lowered
Continuous use at a maintenance dose is likely the more effective strategy for most people
Well-known GLP-1 medications include semaglutide (brand names Ozempic and Wegovy) and liraglutide (brand names Saxenda and Victoza)

The range of gallbladder complications linked to Ozempic spans from mild to life-threatening: Acute cholecystitis requiring emergency hospitalization and surgical intervention Cholelithiasis (gallstones) causing severe right upper quadrant pain, especially after fatty meals Biliary colic with episodes of intense pain lasting hours Choledocholithiasis where stones migrate to the common bile duct causing obstruction Ascending cholangitis, a life-threatening infection of the bile ducts Pancreatitis secondary to gallstone migration Post-cholecystectomy syndrome with ongoing digestive problems after gallbladder removal Increased surgical risks due to delayed gastric emptying affecting anesthesia safety FDA investigations revealed particularly concerning patterns, with 47% of acute cholecystitis cases developing within 90 days of starting Ozempic, suggesting an immediate and dramatic effect on gallbladder function

HbA1c is a measurement of the amount of glucose bound to the heme found in red blood cells